RS54456B1 - Tretman akutne limfoblastne leukemije - Google Patents

Tretman akutne limfoblastne leukemije

Info

Publication number
RS54456B1
RS54456B1 RS20150797A RSP20150797A RS54456B1 RS 54456 B1 RS54456 B1 RS 54456B1 RS 20150797 A RS20150797 A RS 20150797A RS P20150797 A RSP20150797 A RS P20150797A RS 54456 B1 RS54456 B1 RS 54456B1
Authority
RS
Serbia
Prior art keywords
chain antibody
bispecific single
patient
mrd
patients
Prior art date
Application number
RS20150797A
Other languages
English (en)
Serbian (sr)
Inventor
Gerhard Zugmaier
Evelyn Degenhard
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41692882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS54456(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of RS54456B1 publication Critical patent/RS54456B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20150797A 2008-11-07 2009-11-06 Tretman akutne limfoblastne leukemije RS54456B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US18329109P 2009-06-02 2009-06-02
PCT/EP2009/007970 WO2010052014A1 (en) 2008-11-07 2009-11-06 Treatment of acute lymphoblastic leukemia

Publications (1)

Publication Number Publication Date
RS54456B1 true RS54456B1 (sr) 2016-06-30

Family

ID=41692882

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20150797A RS54456B1 (sr) 2008-11-07 2009-11-06 Tretman akutne limfoblastne leukemije
RS20190593A RS58827B1 (sr) 2008-11-07 2009-11-06 Tretiranje akutne limfoblastne leukemije

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20190593A RS58827B1 (sr) 2008-11-07 2009-11-06 Tretiranje akutne limfoblastne leukemije

Country Status (26)

Country Link
US (3) US20130323247A1 (enExample)
EP (2) EP2342227B1 (enExample)
JP (2) JP5647132B2 (enExample)
KR (1) KR101695327B1 (enExample)
CN (2) CN107184977A (enExample)
AU (4) AU2009313040B2 (enExample)
BR (1) BRPI0921482B1 (enExample)
CA (1) CA2742249C (enExample)
CY (2) CY1117033T1 (enExample)
DK (2) DK2982696T3 (enExample)
ES (2) ES2727585T3 (enExample)
HR (2) HRP20151168T1 (enExample)
HU (2) HUE043326T2 (enExample)
IL (1) IL212652A (enExample)
LT (1) LT2982696T (enExample)
ME (2) ME03480B (enExample)
MX (1) MX2011002927A (enExample)
NZ (1) NZ591311A (enExample)
PL (2) PL2982696T3 (enExample)
PT (2) PT2342227E (enExample)
RS (2) RS54456B1 (enExample)
RU (1) RU2536940C2 (enExample)
SI (2) SI2342227T1 (enExample)
SM (2) SMT201900278T1 (enExample)
WO (1) WO2010052014A1 (enExample)
ZA (1) ZA201103255B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1976886T1 (sl) * 2005-12-16 2015-03-31 Amgen Research (Munich) Gmbh Sredstva in postopki za zdravljenje tumorskih bolezni
AU2009313040B2 (en) * 2008-11-07 2015-07-09 Amgen Research (Munich) Gmbh Treatment of acute lymphoblastic leukemia
PL2493503T5 (pl) 2009-10-27 2021-05-31 Amgen Research (Munich) Gmbh Schemat dawkowania do podawania dwuswoistego przeciwciała CD19xCD3
LT3412687T (lt) * 2010-10-27 2020-07-27 Amgen Research (Munich) Gmbh Didžiųjų b ląstelių difuzinės limfomos gydymo būdai
SMT201700250T1 (it) * 2010-11-10 2017-07-18 Amgen Res Munich Gmbh Prevenzione di effetti avversi provocati da domini leganti cd3 specifici
ES2806142T3 (es) * 2011-04-28 2021-02-16 Amgen Res Munich Gmbh Pauta posológica para administrar un anticuerpo biespecífico CD19xCD3 a pacientes en riesgo de posibles efectos adversos
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP3105252B1 (en) * 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
DK3149480T3 (en) 2014-05-30 2019-04-01 Amgen Res Munich Gmbh RISK CRAFIFICATION OF PATIENTS WITH B-PRECURSOR ACUTE Lymphatic Leukemia
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
WO2016109549A1 (en) * 2014-12-30 2016-07-07 University Of Utah Research Foundation Hdac1,2 inhibitors and methods of using the same
SG11201705988UA (en) 2015-02-24 2017-08-30 Bioatla Llc Conditionally active biological proteins
IL255697B2 (en) 2015-05-18 2023-11-01 Tcr2 Therapeutics Inc Compositions and methods for TCR programming using fusion proteins
EP4523759A3 (en) 2015-05-20 2025-06-11 Amgen Research (Munich) GmbH B-cell depletion as a diagnostic marker
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN105154440B (zh) * 2015-08-14 2016-11-30 深圳市瀚海基因生物科技有限公司 一种基于高通量测序构建白血病微小残留病灶tcr文库的多重pcr引物和方法
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
ES2912729T3 (es) 2015-11-03 2022-05-27 Janssen Biotech Inc Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
CN109715668A (zh) 2016-08-02 2019-05-03 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
CN111315780A (zh) * 2017-12-11 2020-06-19 安进公司 双特异性抗体产品的连续制造工艺
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) * 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
AU2020214336A1 (en) * 2019-01-30 2021-09-09 The Wistar Institute Of Anatomy And Biology DNA-encoded bispecific T-cell engagers targeting cancer antigens and methods of use in cancer theraputics
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2021014644A (es) * 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN116829183A (zh) 2020-09-16 2023-09-29 美国安进公司 施用治疗剂量的双特异性t细胞接合分子治疗癌症的方法
MX2024004617A (es) 2021-10-15 2024-06-19 Amgen Res Munich Gmbh Administracion subcutanea de anticuerpos acopladores a linfocitos t de union a cd19.
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
KR100508289B1 (ko) * 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
BG65066B1 (bg) * 1998-04-21 2007-01-31 Micromet Gessellschaft Fur Biomedicinische Forschung Mbh CD19 x CD3 СПЕЦИФИЧНИ ПОЛИПЕПТИДИ И ТЯХНОТО ИЗПОЛЗВАНЕ
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
PL1673398T3 (pl) * 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
SI1976886T1 (sl) * 2005-12-16 2015-03-31 Amgen Research (Munich) Gmbh Sredstva in postopki za zdravljenje tumorskih bolezni
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
SI2059536T1 (sl) * 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
AU2009313040B2 (en) * 2008-11-07 2015-07-09 Amgen Research (Munich) Gmbh Treatment of acute lymphoblastic leukemia
RU2538965C2 (ru) * 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
MX2011007681A (es) * 2009-01-19 2011-08-08 Abbott Lab Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
WO2010138578A1 (en) * 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
AU2010295717B2 (en) * 2009-09-20 2014-09-11 Abbvie Inc. ABT-263 crystalline forms and solvates for use in treating Bcl-2 protein related diseases
PL2493503T5 (pl) * 2009-10-27 2021-05-31 Amgen Research (Munich) Gmbh Schemat dawkowania do podawania dwuswoistego przeciwciała CD19xCD3

Also Published As

Publication number Publication date
KR20110091668A (ko) 2011-08-12
EP2982696A3 (en) 2016-02-17
ME02363B (me) 2016-06-20
SI2982696T1 (sl) 2019-06-28
EP2342227B1 (en) 2015-10-07
RU2011122819A (ru) 2012-12-20
SMT201500328B (it) 2016-02-25
HUE028175T2 (en) 2016-12-28
HK1158668A1 (en) 2012-07-20
EP2982696B1 (en) 2019-03-27
HUE043326T2 (hu) 2019-08-28
RS58827B1 (sr) 2019-07-31
HRP20151168T1 (hr) 2015-12-04
ES2558434T3 (es) 2016-02-04
NZ591311A (en) 2012-10-26
JP5647132B2 (ja) 2014-12-24
CY1122366T1 (el) 2021-01-27
US20190300609A1 (en) 2019-10-03
AU2018260815A1 (en) 2018-11-22
HRP20190912T1 (hr) 2019-07-26
WO2010052014A1 (en) 2010-05-14
BRPI0921482A2 (pt) 2016-01-12
DK2342227T3 (en) 2016-02-15
AU2009313040A1 (en) 2010-05-14
JP2015057417A (ja) 2015-03-26
AU2009313040B2 (en) 2015-07-09
BRPI0921482B1 (pt) 2022-09-20
US11597766B2 (en) 2023-03-07
MX2011002927A (es) 2011-04-11
IL212652A0 (en) 2011-07-31
CA2742249A1 (en) 2010-05-14
SI2342227T1 (sl) 2015-12-31
CN102209728A (zh) 2011-10-05
US20240109964A1 (en) 2024-04-04
LT2982696T (lt) 2019-06-10
BRPI0921482A8 (pt) 2017-07-11
CY1117033T1 (el) 2017-04-05
US20130323247A1 (en) 2013-12-05
DK2982696T3 (da) 2019-05-27
EP2982696A2 (en) 2016-02-10
CN107184977A (zh) 2017-09-22
JP2012508164A (ja) 2012-04-05
ES2727585T3 (es) 2019-10-17
IL212652A (en) 2015-05-31
SMT201900278T1 (it) 2019-07-11
AU2017219083A1 (en) 2017-09-14
PT2342227E (pt) 2015-11-13
AU2015238784A1 (en) 2015-10-29
CA2742249C (en) 2020-07-21
KR101695327B1 (ko) 2017-01-11
HK1220705A1 (en) 2017-05-12
AU2017219083B2 (en) 2018-08-09
ME03480B (me) 2020-01-20
PT2982696T (pt) 2019-06-04
RU2536940C2 (ru) 2014-12-27
PL2342227T3 (pl) 2016-04-29
EP2342227A1 (en) 2011-07-13
AU2018260815B2 (en) 2020-03-05
JP5955921B2 (ja) 2016-07-20
PL2982696T3 (pl) 2019-08-30
ZA201103255B (en) 2013-12-23

Similar Documents

Publication Publication Date Title
US20240109964A1 (en) Treatment of acute lymphoblastic leukemia
RU2536933C2 (ru) Новое лечение острого лимфобластного лейкоза у детей
HK1220705B (en) Treatment of acute lymphoblastic leukemia
HK1158668B (en) Treatment of acute lymphoblastic leukemia
HK40022438A (en) Treatment of pediatric acute lymphoblastic leukemia
HK1158667B (en) Treatment of pediatric acute lymphoblastic leukemia